Nordøy A
Department of Medicine, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway.
Minerva Med. 2002 Oct;93(5):357-63.
Dyslipidemia including hypercholesterolemia and hypertriglyceridemia often associated with low levels of HDL-cholesterol is a common and important cluster of risk factors for coronary heart disease. Dyslipidemia is also commonly associated with hypertension, hyperinsulinemia and central obesity in the metabolic syndrome. Lifestyle adjustments including increased physical activity and dietary modifications leading to weight reduction are important first steps in the prevention of coronary heart disease in patients with such abnormalities in lipid metabolism. When these adjustments are insufficient to achieve desirable results, the combined treatment with statins and omega-3 fatty acids is an efficient treatment alternative. Both statins and omega-3 fatty acids have documented their effects against coronary heart disease (CHD) both in primary and secondary prevention trials. The mechanisms involved are only partly explained, however, the synergistic effects of statins and omega-3 fatty acids significantly reduce the risk for CHD in patients with dyslipidemia.
血脂异常,包括高胆固醇血症和高甘油三酯血症,常与高密度脂蛋白胆固醇水平低相关,是冠心病常见且重要的一组危险因素。血脂异常在代谢综合征中也通常与高血压、高胰岛素血症和中心性肥胖相关。生活方式调整,包括增加体力活动和饮食改变以减轻体重,是预防脂质代谢异常患者冠心病的重要第一步。当这些调整不足以取得理想效果时,他汀类药物和ω-3脂肪酸联合治疗是一种有效的治疗选择。他汀类药物和ω-3脂肪酸在一级和二级预防试验中均已证明其对冠心病(CHD)的疗效。然而,其中涉及的机制仅得到部分解释,他汀类药物和ω-3脂肪酸的协同作用显著降低了血脂异常患者患冠心病的风险。